Cure My Disease

Don't miss your cure!

 Log in / Sign up

A blood marker may reveal hidden heart risk in rheumatoid arthritis

NCT ID NCT07793747

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

This study looks at whether a blood protein called asprosin is linked to metabolic syndrome and heart risk in people with rheumatoid arthritis. Researchers will compare asprosin levels in three groups: rheumatoid arthritis patients with metabolic syndrome, those without it, and healthy controls. Participants give blood samples and undergo clinical assessments, including disease activity and physical function. The goal is to see if asprosin could serve as a marker for cardiometabolic risk in this population.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Measurement of serum asprosin levels via blood test (ELISA); no drug or intervention is given.
What this could lead to
If asprosin levels track with metabolic syndrome and heart risk in rheumatoid arthritis, doctors might use it as a blood marker to better identify patients who need closer heart monitoring.
What could go wrong
This is an observational study with a small group of 75 people, so the findings may not apply broadly. Asprosin's role is still unclear, and the study cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients aged 18 years and older diagnosed with rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria, recruited from the inpatient and outpatient clinics of the Rheumatology, Rehabilitation, and Physical Medicine Department at Assiut University Hospital, along with age- and sex-matched healthy control individuals.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients aged 18 years or older. * Diagnosis of rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria. * Ability and willingness to provide written informed consent. * Healthy controls: Age- and sex-matched individuals without rheumatoid arthritis or systemic inflammatory diseases. Exclusion Criteria: * Presence of other autoimmune diseases or overlap syndromes. * Active acute or chronic infectious diseases. * Pregnancy or lactation. * Current malignancy or previous history of malignancy. * Severe hepatic or renal impairment. * Receipt of medications primarily prescribed for weight reduction or agents known to markedly alter lipid or glucose metabolism, other than standard rheumatoid arthritis therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome Arachnodactyly cardiovascular disorder Insulin Resistance metabolic syndrome X rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases Metabolic syndrome Rheumatoid arthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.